跳至主要内容
临床试验/NCT04842838
NCT04842838尚未招募不适用

Comparative Clinical Study of Drug-coating Balloon Strategy and Drug-eluting Stent Strategy in the Treatment of True Bifurcation Coronary Artery Disease

Peking University Third Hospital1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2021年6月30日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
1,000
试验地点
1
主要终点
Number of Participants with Target lesion failure (TLF)

研究概览

简要总结

The trial aims to evaluate the long-term clinical outcome of the DCB-only technique is non-inferior to the provisional T stenting with DES in the patients who have 'true' bifurcation lesions.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • At least 18 years old;
  • Evidence of myocardial ischemia and indications of PCI, stable or unstable angina pectoris, or old myocardial infarction;
  • Primary and bifurcated coronary artery lesions (Medina classification 1,1,1 or 1,0,1 or 0,1,1);
  • Visual angiography of the main branch reference vessel diameter ≥2.5mm, and ≤4.0mm;Branch reference vessel diameter ≥2.0mm;
  • Diameter stenosis of main and branch lesions ≥ 70%, and diameter stenosis of branch lesions ≥ 50%;
  • Visual examination of residual stenosis of main branch lesions after pre-dilation ≤ 30% without vascular dissection or dissection with NHLBI classification A, B, C type.
  • If 2 bifurcation lesions meet the inclusion requirements, only 1 lesion can be included in the study, and the other lesion can be treated or not treated as a non-target lesion.

排除标准

  • Main branch or branching target lesions require treatment with more than one device (DES or DCB);
  • There is more than 1 non-target lesion requiring intervention on the target blood vessel;
  • The distance between non-target lesion and target lesion is less than 10 mm;
  • Main and branch lesions > 26 mm or branch lesions length BBB> mm;
  • Left main lesion and its bifurcation lesion;
  • Intra-stent restenosis or severe calcification;
  • ST-segment elevation or non-ST-segment elevation myocardial infarction 7 days before surgery;
  • Severe heart failure (NYHA-IV or left ventricular ejection fraction <35%);
  • Cardiogenic shock;
  • known to have renal failure (EGFR <30ml/min/1.73m2);
  • Pregnant or lactating women, or women of reproductive age who had family planning or were unable to take adequate contraceptive measures during the study period;
  • Any known allergic reactions or contraindications to the drug and coating or scaffold metal required for DCB in the study;
  • Other DES or DCB treatment contraindications;
  • Failing to sign an informed consent or having an expected life of less than 12 months;
  • Other researchers consider it inappropriate to participate in this study.

结局指标

主要结局

Number of Participants with Target lesion failure (TLF)

时间窗: 12 months

Target lesion failure, defined as cardiac death, clinically driven target vessel myocardial infarction and target lesion revascularization.

Number of Participants with net adverse clinical cardiovascular events (NACCE)

时间窗: 12 months

Net adverse clinical cardiovascular events, defined as cardiac death, clinically driven target vessel myocardial infarction, target lesion revascularization and major bleeding (BARC type 2, 3, 5 bleeding)

次要结局

  • Technical success rate(1-2 days)
  • DAPT using time(1/6/12/24/36 month)
  • Clinical procedure time(during the procedure)
  • Number of Participants with ARC defines stent thrombosis(1/6/12/24/36 month)
  • Number of Participants with Bleeding events(BARC2, 3, and 5)(1/6/12/24/36 month)
  • Number of Participants with Target lesion failure (TLF)(1/6/24/36 month)
  • Number of Participants with Target vessel revascularization (TVR)(1/6/12/24/36 month)
  • Number of Participants with Target lesion revascularization (TLR)(1/6/12/24/36 month)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验